Pegloticase Disease Interactions
There are 2 disease interactions with pegloticase:
Pegloticase/Rasburicase (Includes Pegloticase) ↔ G6Pd Deficiency
Severe Potential Hazard, High plausibility
Applies to: G-6-PD Deficiency
The antihyperuricemic agents pegloticase and rasburicase are contraindicated in patients deficient in glucose-6-phosphate-dehydrogenase (G6PD), as these have shown to cause severe hemolytic reactions and methemoglobinemia. Patients at high risk of G6PD deficiency such as patients of African, Mediterranean or Southern Asian ancestry, should be screened prior to starting treatment. Treatment with any of these drugs should be discontinued immediately and permanently in any patient developing hemolysis or methemoglobinemia.
Pegloticase (Includes Pegloticase) ↔ Congestive Heart Failure
Moderate Potential Hazard, Moderate plausibility
Applies to: Congestive Heart Failure
Pegloticase has not been formally studied in patients with congestive heart failure, and some patients in clinical trials have experienced exacerbation. Caution should be exercised when using pegloticase in these patients and close monitoring following the infusion is recommended.
pegloticase drug Interactions
There are 14 drug interactions with pegloticase
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.